Business Wire
Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation
📈
AI Sentiment
Highly Positive
9/10
- Home
- HRMY
as of 11-28-2025 12:33pm EST
$35.22
$0.34
-0.96%
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Chart Type:
Time Range:
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | PLYMOUTH MEETING |
| Market Cap: | 2.0B | IPO Year: | 2020 |
| Target Price: | $50.56 | AVG Volume (30 days): | 934.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 3.17 | EPS Growth: | 50.44 |
| 52 Week Low/High: | $25.52 - $40.93 | Next Earning Date: | 11-04-2025 |
| Revenue: | $825,944,000 | Revenue Growth: | 21.13% |
| Revenue Growth (this year): | 20.68% | Revenue Growth (next year): | 15.93% |
AI-Powered HRMY Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 75.17%
75.17%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Harmony Biosciences Holdings Inc. (HRMY)
Kapadia Sandip
Sell
CHIEF FINANCIAL OFFICER
HRMY Nov 21, 2025
Avg Cost/Share
$35.00
Shares
3,427
Total Value
$119,945.00
Owned After
0
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Kapadia Sandip | HRMY | CHIEF FINANCIAL OFFICER | Nov 21, 2025 | Sell | $35.00 | 3,427 | $119,945.00 | 0 |
Latest Harmony Biosciences Holdings Inc. News
HRMY Breaking Stock News: Dive into HRMY Ticker-Specific Updates for Smart Investing
Compare HRMY vs Leading Stocks
See how HRMY stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "HRMY Harmony Biosciences Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.